Table 1.

Natural receptor- and ligand-based CARs are currently in preclinical and clinical development.

	Receptor Antigen	Ligand	Indication	Phase of Development	Clinical Trial	Status	Ref
Natural receptor-based CAR T cells	B7H6	NKp30	various	Preclinical			[66,67]
	DNAM-1	PVR, Nectin-2	various	Preclinical			[68,69]
	NKG2D	MICA, MICB, ULBP1-6	various	Clinical	NCT02203825 NCT03018405 NCT03310008 NCT03612739 NCT03466320 NCT04167696 NCT03692429 NCT04991948	Completed Unknown Active Withdrawn Completed Recruiting Recruiting Recruiting	[70,71,72,73,74,75,76,77,78,79,80,81,82,83]
	CD27	CD70	various	Clinical	NCT02830724	Suspended	[84,85,86]
	CD16	Fc	various	Clinical	NCT02776813 NCT03266692 NCT03189836 NCT03680560 NCT02840110	Completed Terminated Terminated Terminated Terminated	[87,88,89,90]
Ligand-based CAR T cells	EGFR	E3 Adnectin	Solid tumors	Preclinical			[91]
	FLT3	FLT3L	AML	Preclinical			[92,93]
	IL-10R	IL-10	AML	Preclinical			[94]
	MPL	TPO	AML	Preclinical			[63]
	IL-11Rα	IL-11	OS	Preclinical			[95]
	EPHB4	EPHRIN B2	RMS	Preclinical			[96]
	unknown	CTLX	GBM	Preclinical			[97]
	IL-13Rα2	E13Y IL-13	GBM	Clinical	NCT02208362 NCT04003649 NCT04510051 NCT04661384	Recruiting Recruiting Recruiting Recruiting	[56,98,99,100,101]
	ErbB family	T1E	HNSCC	Clinical	NCT01818323	Recruiting	[102,103,104,105]
	BCMA, TACI	APRIL	MM	Clinical	NCT03287804 NCT04657861	Terminated Not yet recruiting	[106,107]
	BCMA, TACI	TriPRIL	MM	Clinical	NCT05020444	Recruiting	[57]
	unknown	CTLX	GBM	Clinical	NCT04214392	Recruiting	[108]
	ICAM-I	LFA-1	Thyroid	Clinical	NCT04420754	Recruiting	[109,110,111]
	FSHR	FSH	Ovarian	Clinical			[112,113]
	GMR	GM-CSF	AML, JMML	Clinical	jRCT2033210029	Recruiting	[62,114]